替罗非班联合瑞替普酶治疗ST段抬高性急性心肌梗死的效果分析  

The Effect of Tirofiban Combined with Reteplas in Acute ST Elevation Myocardial Infarction

作　　者：曾小曼[1] 林道德[1] 王栋[1] 高艳红[1] ZENG Xiao-man LIN Dao-de WANG Dong GAO Yan-hong(Wenchang People＇s Hospital, Wenchang 571300, China)

机构地区：[1]海南省文昌市人民医院,海南文昌571300

出　　处：《中国医药指南》2017年第10期14-15,共2页Guide of China Medicine

摘　　要：目的探讨替罗非班联合瑞替普酶治疗ST段抬高性急性心肌梗死的临床效果。方法选择134例ST段抬高性心肌梗死患者,随机分为观察组和对照组,对照组给予常规瑞替普酶剂量治疗,观察组给予半剂量瑞替普酶联合替罗非班治疗。观察两组血管再通及并发症发生情况。结果观察组血管再通率为74.6%,对照组血管再通率为61.1%,观察组血管再通发生率高于对照组,差异有统计学意义(P<0.05)。观察组出血并发发生率和对照组近似,差异无统计学意义(P>0.05)。结论替罗非班联合半剂量瑞替普酶能够提高ST段抬高性心肌梗死患者冠状动脉血管再通率,且并不增加出血并发症发生率,效果显著。Objective To explore the effects of tirofiban combined with reteplase treatment in acute ST segment elevation myocardial infarction. Methods134 patients with ST segment elevation myocardial infarction, were randomly divided into observation group and control group, the control group was given routine dose reteplase treatment, the observation group was given half dose tirofiban combined with reteplase. The recanalization and complications of the two groups were observed. Results The rate of vascular reperfusion in the observation group was 74.6%, the rate of vascular reperfusion in the control group was 61.1%, the recanalization rate of the observation group was higher than that of the control group, the difference was statistically significant（P〈0.05）. The incidence of bleeding in the observation group was similar to that in the control group, the difference was not statistically significant（P〉0.05）. ConclusionTirofiban combined with half dose reteplase can improve coronary artery revascularization rate of patients with ST segment elevation myocardial infarction, and which does not increase the incidence of bleeding complications, the therapy has significant effect.

关 键 词：ST段抬高性急性心肌梗死 替罗非班 瑞替普酶 血管再通 

分 类 号：R542.22[医药卫生—心血管疾病]